Sosei Group Corporation - Articles and news items

Heptares announces positive outcome of Phase 1a study of HTL9936

Industry news / 17 June 2015 / Victoria White

Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, has announced the positive outcome of its Phase 1a study with HTL9936…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+